Cerevel Therapeutics, a company focused on neuroscience diseases, announced the completion of its merger with Arya Sciences Acquisition Corp II (Nasdaq: ARYBU). Cerevel Therapeutics will commence trading its shares under the symbol “CERE” and its warrants under the symbol “CEREW” today on the Nasdaq. Net proceeds totaled approximately $440 million, which included funds held in Arya II’s trust account and the concurrent PIPE financing. Arya II shareholders approved the transaction Oct. 26. Cerevel Chairman and Chief Executive Officer Tony Coles, M.D., will continue to lead the combined company. Read more.
Related Posts
Gores Holdings VIII Completes $345M IPO
The SPAC's potential targets include companies in industrials, technology, telecom, media and entertainment, business services, healthcare, and consumer products.
Lionheart Acquisition II Sets Vote Date on $32.6B MSP Recovery Deal
The transaction is anticipated to generate gross proceeds of up to approximately $230 million of cash, assuming no redemptions by Lionheart’s public stockholders.
Williams Rowland Acquisition will Redeem Shares and Liquidate
The SPAC's shares will cease trading on the NYSE American as of Feb. 29.
Lightning eMotors SPAC Deal Insiders Allegedly Harmed Company
Electric vehicle maker Lightning eMotors has lost much of its value and faces mounting costs because of board members and officers’ misrepresentations before and after it went public in a merger with a blank-check company, investors allege.